SEC Form DEF 14A filed by Regeneron Pharmaceuticals Inc.
$REGN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2026 | $700.00 | Buy → Neutral | Citigroup |
| 5/18/2026 | $641.00 | Outperform → Market Perform | Leerink Partners |
| 3/31/2026 | $875.00 | Overweight | Piper Sandler |
| 3/6/2026 | $923.00 | Overweight | Barclays |
| 1/7/2026 | $860.00 | Underperform → Buy | BofA Securities |
| 12/3/2025 | $767.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/24/2025 | $798.00 | Buy | Truist |
| 11/24/2025 | $255.00 | Buy | HSBC Securities |
Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo Maftivimab has been recommended to be studied as a monotherapy in the current outbreak TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU). The MAA is supported by data from the pivotal CHORD clinical trial, in which 24 parti
Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in.NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab). Those who lost money on REGN are encouraged to submit their information to SueWallSt. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueW
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
Citigroup downgraded Regeneron Pharma from Buy to Neutral and set a new price target of $700.00
Leerink Partners downgraded Regeneron Pharma from Outperform to Market Perform and set a new price target of $641.00
Piper Sandler resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $875.00
For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis
TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,
TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application submitted; cemdisiran could be the first siRNA to be approved for the treatment of gMG Regeneron to host virtual ‘Regeneron Roundtable: gMG & C5 Complement Program' investor event on Wednesday, April 22 at 8:30 a.m. ET TARRYTOWN, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis (gMG) w
TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detail
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)